Although carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) are commonly used in clinical practice for tumor markers, they have limited specificity and sensitivity to screen patients with early pancreatic ductal adenocarcinoma (PDAC) [3]. Here, CEACAM5 is linked to pancreatic ductal adenocarcinoma.